Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00. Following the transaction, the president now owns 2,936,467 shares of the company's stock, valued at $31,772,572.94. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Songjiang Ma also recently made the following trade(s):

GYRE traded up $1.06 on Monday, hitting $12.20. The company had a trading volume of 111,450 shares, compared to its average volume of 75,000. The business's fifty day simple moving average is $12.86 and its 200 day simple moving average is $12.61. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $30.39.

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC bought a new position in Gyre Therapeutics during the 3rd quarter valued at about $47,000. Barclays PLC grew its stake in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company's stock valued at $116,000 after buying an additional 6,855 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Gyre Therapeutics in the second quarter worth approximately $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics during the 2nd quarter valued at $218,000. Hedge funds and other institutional investors own 23.99% of the company's stock.

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Gyre Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.

While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.